News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

LeadStar Marketplace Unleashes Groundbreaking Enhancements to Its Lead-Generation Platform

AmeriLife

LeadStar Marketplace, the proprietary, private leads platform created exclusively for AmeriLife -affiliated agents, announced today the launch of LeadStar 2.0, which features significant enhancements to its robust platform, designed to revolutionize how licensed insurance agents acquire quality leads for consumers seeking Medicare, Medicare Advantage, Affordable Care Act (ACA), and Final Expense (FE) insurance coverage. LeadStar 2.0 is available immediately to all existing customers. In collaboration with its customer base and affiliated health agencies, the LeadStar team has listened to what sales professionals value in today’s lead generation landscape, resulting in the upgraded LeadStar 2.0 platform. The platform’s enhanced approach to supplying leads features an extended lead catalog, multi-media channel capabilities, and advanced optimization technologies to set a new standard for lead generation efficiency and effectiveness. “At LeadStar, we are dedicated to pushing the boundaries of what's possible in lead generation,” said William DeCourcy, Chief Lead Generation Officer for AmeriLife. “These enhancements are a testament to our ongoing efforts to innovate and improve our services. We believe the new features will empower our clients to succeed even more in their marketing and sales endeavors.” The enhanced LeadStar 2.0 platform is designed to meet the demands of the evolving health and life insurance marketplace, ensuring licensed agents connect with the right prospects more efficiently than before. Extended Lead Catalog The extended lead catalog allows users to diversify and target a more comprehensive network of potential customers across various multimedia platforms and demographics. This expansion means agents can connect with the right prospects at the right time, which should dramatically increase conversion rates. LeadStar 2.0’s expansion targets social media, inbounds, direct mail, and transfers with real-time data across Medicare, MA, ACA, and FE. This deeper level of marketing funnel visibility offers more substantial visibility to each lead by understanding their customer journey before the sales process begins. Expanded Multimedia Channel Supply LeadStar 2.0 integrates a wealth of multi-media channel leads into its platform. Agents can now connect with potential customers through multiple touchpoints, including social media, email, and mobile, all within a unified system tailored to meet specific needs or strategies. This holistic approach streamlines the lead generation process, enhances user engagement and interaction, and aims to provide the lowest CPA possible. More Substantial Lead Delivery Moreover, LeadStar 2.0 introduces enhanced optimization capabilities to its platform. Advanced algorithms and machine learning power the platform and offer more intelligent lead matching and predictive lead scoring. These features ensure clients receive relevant and high-potential leads, reducing the time and effort they will spend on lead qualification and follow-up. For more information about LeadStar and the enhanced lead-generation platform, please email leadstar@leadstarhub.com or request access at LeadStarHub.com. ### About LeadStar LeadStar is an industry-leading enterprise leads program that delivers the compliant, reliable, and performative leads that today’s health and life insurance agents need to grow their books of business and maximize their success. Powered by AmeriLife and exclusively for the company’s affiliated agents, LeadStar’s suite of solutions includes LeadStar Marketplace, LeadStar Connect, and LeadStar Direct. For more information, contact an AmeriLife-affiliated marketing company or visit LeadStarHub.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado Media@amerilife.com Company Website https://amerilife.com/

July 18, 2024 12:00 PM Eastern Daylight Time

Article thumbnail News Release

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma

After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life. Dr. Uttam Patil shared with Steve Darling from Proactive that the study aims to gain a deeper understanding of the prevalence and impact of depression in cancer patients. It will explore innovative therapeutic approaches by integrating real-time patient monitoring and enhanced patient analysis through an AI model. This advanced methodology is expected to increase the lead time for clinical trials, utilizing novel and sophisticated treatment protocols. The clinical study will be conducted at the renowned Cedars-Sinai Medical Center, involving cancer patients who experience depressive symptoms. By leveraging advanced AI technologies and employing cutting-edge diagnostic and therapeutic techniques, the study aims to monitor and treat depression in participants under meticulous medical supervision. Dr. Patil emphasized that the integration of AI-driven solutions in this clinical study represents a significant leap forward in the treatment of depression in cancer patients. The use of real-time patient monitoring and AI-based analysis is anticipated to provide valuable insights and improve patient outcomes, setting a new standard for clinical trials in this area. The collaboration between ABVC BioPharma and AiBtl BioPharma highlights their commitment to advancing healthcare through innovative solutions. This study is poised to make a substantial impact on the management of depression in cancer patients, offering hope for improved quality of life and better treatment outcomes. Through this pioneering study, ABVC BioPharma and AiBtl BioPharma are at the forefront of integrating technology with healthcare, paving the way for future advancements in the field. The companies are dedicated to utilizing AI to enhance patient care and accelerate the development of effective treatments for depression in cancer patients. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 18, 2024 10:31 AM Eastern Daylight Time

Video
Article thumbnail News Release

Forum Health Breaks into Denver Market with Acquisition of Concierge Functional and Regenerative Medicine Practice

Forum Health

Forum Health, LLC, a nationwide network of integrative and functional medicine providers and a pioneer in personalized healthcare, is expanding into a leading wellness-focused city with its acquisition of RevolutionaryMD in Denver, CO. Learn more about RevolutionaryMD. Renowned for its proclivity for health and wellness and prestigious medical research institutions, Denver is the ideal setting for a clinic rooted in personalized, cutting-edge healthcare. Phil Hagerman, Forum Health CEO: “Dr. Grover’s development of his revolutionary functional, regenerative, and anti-aging medical center aligns perfectly with the Forum Health clinic model, making this expansion a natural fit. His thirty years of success and expertise in central Denver is invaluable as we expand to a new state, enhancing the practice’s availability and offerings for wellness-focused patients.” The founder of RevolutionaryMD center in Cherry Creek North, Fred Grover, Jr., MD, is a Board-Certified Family Physician with training and certifications in Integrative, Functional, and Anti-Aging Medicine. He brings a wealth of experience and expertise to Forum Health's expanding network. Fred Grover Jr., MD, RevolutionaryMD Founder: “I’m excited to join Forum Health and grow our services and availability to help patients find a proactive approach to healthcare. We embrace the future of medicine by offering a robust preventative care model to treat the root cause of chronic conditions.” In addition to traditional testing, RevolutionaryMD offers genomic panels, advanced cardiovascular and cancer screening, inflammatory, and nutritional testing. It also employs AI for precise, personalized recommendations, moving beyond the depersonalized, often suboptimal outcomes of standard allopathic medicine. RevolutionaryMD has pioneered the concierge approach of functional medicine, advancing personalized healthcare with the latest treatments in: Anti-Aging and Regenerative Medicine for Improved Healthspan and Lifespan Bioidentical Hormone Replacement Therapy and Restoration Sexual Health and Wellness Aesthetic Dermatology Mind and Body Balancing Through Brain Health Modalities Integrated Ketamine and Sound Therapy for Depression IV Therapy for Post-COVID Syndrome, Inflammation and Healthy Mitochondrial Function Dr. Grover's dedication to functional and integrative medicine is evident in his role as an assistant clinical professor at the University of Colorado, Denver, his Board Certifications in Anti-Aging and Integrative Holistic Medicine, and his authorship of "Spiritual Genomics" and "Awakening Gaia." About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

July 18, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

Ascend Wellness CEO Outlines Company's Growth Strategy and Market Expansion Plans

Ascend Wellness Holdings

Ascend Wellness CEO John Hartman joined Steve Darling from Proactive to discuss the company’s current status and future plans. Ascend Wellness, a prominent multi-state cannabis operator in the United States, has established its presence primarily in the Midwest, Northeast, and Mid-Atlantic regions. The company, now in its fifth year of operation, has expanded its footprint to seven states, including Ohio and Pennsylvania, both of which are transitioning to recreational cannabis use. During the interview, Hartman emphasized Ascend Wellness's strategic approach of focusing on select markets and maximizing the number of dispensaries allowed in each state. This targeted strategy is aimed at optimizing market penetration and ensuring robust growth. Drawing on his extensive background in wholesale, retail, and manufacturing, Hartman highlighted the company's emphasis on effective capital deployment and growth through mergers and acquisitions (M&A). A significant development discussed was the refinancing of a term loan due in August 2025. This financial maneuver provides Ascend Wellness with a five-year runway to concentrate on growth initiatives. The refinancing is expected to enhance the company's balance sheet management, providing greater financial stability and flexibility. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 17, 2024 10:42 AM Eastern Daylight Time

Video
Article thumbnail News Release

Briefly Bio launches with $1.2m funding to help scientists reproduce complex experiments

Briefly Bio

Science is in a reproducibility crisis. In preclinical research, it’s estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year. Solving this problem, techbio startup Briefly Bio has launched with software that makes lab work more reproducible by helping scientists capture and share their work clearly and consistently. With this launch, Briefly Bio has secured a $1.2m pre-seed funding round. It was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. Biological experiments have become increasingly complex. With this growing complexity, details that are critical to our shared understanding are often undocumented and lost. This makes scientific collaboration inefficient: lab scientists struggle to reproduce and build on top of each other's experiments; data scientists do not have the necessary context to analyse the data produced in their labs; and automation teams lack all details to build robotic labs. Briefly Bio is tackling this, creating a shared language for experiments that is consistent across scientists, and clear for any collaborator to understand. Their software uses AI to convert existing experiment descriptions into this consistent format, while automatically filling in gaps and spotting errors. This helps capture the value of every experiment that is run, and enables scientists to learn from each other’s work. Briefly was founded by Dr Katya Putintseva, Harry Rickerby and Staffan Piledahl. They have varied backgrounds, through academia, tech, biotech and robotics. Before founding the company, the three worked together at drug discovery startup LabGenius, where they helped build its ML-driven antibody discovery platform. Harry Rickerby, CEO and co-founder at Briefly Bio, commented: “Scientific methods are a bit like software code, they are a set of instructions that define how an experiment should be run. The majority of this ‘code’ is incomplete, since writing up each experiment completely takes a huge amount of effort. Now, with LLMs, there’s a way to make these methods consistent without imposing on a scientists’ workflow. As Github helped software engineers collaborate and build on each other’s code, we think Briefly can help scientists and engineers do the same with their experiments.” With AI and high throughput experimentation, there is an opportunity for huge improvements in the efficiency of scientific discovery. Hundreds of billions of dollars are being invested through startups and big pharma to take advantage. To realise this potential, science needs more consistency and transparency in how these datasets are generated, since the value of any model is a product of the data it has been trained on. Briefly Bio is building this necessary layer of infrastructure to accelerate scientific discovery in biology. “This is a revolution in documenting lab experiments. It is the future of foolproof knowledge-sharing between scientists” said Dr Gena Nikitin, Founder of Miphic. While Dr Maria Anastasina, Wet Lab Head at the Evolutionary and Synthetic Biology Unit, OIST, added: “Briefly has become a core part of our lab's knowledge base and a great help to me in training researchers and lab management”. And Suparna Kumar, PhD student at Weill Cornell commented: “Briefly Bio has become an indispensable part of my lab routine because it helps me save so much time”. Rob Harkness, CTO of Biosero, added: “We're very excited by what Breifly.Bio can offer with their software tools. Inconsistent and incomplete data can compromise research, making it difficult to reproduce experiments and undermining trust in scientific results. Digitalising and automating laboratory operations can address this, but this effort faces challenges of inefficiency and high error rates, primarily due to the diverse formats in which workflows are presented. Briefly.bio addresses this by converting scientific protocols written in natural language into a common and consistent structured format. This facilitates much faster design and implementation of automated systems, ensuring all critical information is captured and utilized effectively. The result is a significant boost in workflow integration, efficiency, and data quality, all of which are crucial for generating reliable experimental results. This leads to more comprehensive and innovative solutions in lab automation that can only help accelerate scientific research.” Shelby Newsad, Investor at Compound, commented: “The crux of successful science lies in consistent and executable methods. Whereas most bio software companies focus on data and its analysis, Briefly goes upstream to the core problem space of reproducibility via protocols. For the first time in science history, this incentivizes scientists to share more of their previously tacit knowledge. The fact that Briefly-made methods can be built and collaborated upon creates unique potential for network effects from their software.” Briefly Bio is creating a future where scientists can stop reinventing the wheel – spending time and resources on experiments that they can’t reproduce. This will enable scientists to produce datasets that will quickly expand our understanding of biology. About Briefly Bio Briefly Bio is the tool to make lab work reproducible. It helps scientists capture, share their experiments clearly and consistently. Briefly is based in London, UK. For more information, visit https://briefly.bio. About Compound VC Compound is a research-centric, thesis-driven investment firm. We are a team of investors, researchers, and operators. We use our domain expertise, network, and prior experiences to help our founders solve previously unsolvable technical problems, communicate these breakthroughs to the world, and scale commercialization. Contact Details Briefly Bio Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://briefly.bio/

July 17, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

University Compounding Pharmacy Announces Rebrand to MediVera Compounding Pharmacy™

MediVera

University Compounding Pharmacy, a leader in personalized medicine since 1999, today announced it is rebranding as MediVera Compounding Pharmacy™. The rebrand comes at a time when the company is growing strongly due to the introduction of new product offerings, nationwide expansion, and the successful differentiation of its quality products and services. Despite the name change, the company’s ownership and passionate team remain the same, ensuring continuity in the high-level service and exceptional care that healthcare providers and patients have relied on for more than two decades. Over the past few years, the company has seen its revenue grow substantially. New product offerings, nationwide expansion, and strong market positioning through differentiated quality products and services, such as the Impressed Advantage program, have enabled the company to double its revenue from 2022 to 2023. Growth is anticipated to accelerate this year, with the company expecting to double revenue year-over-year once again. “Differentiation is and will continue to be an important growth driver for our company. With the Impressed Advantage customer service program, we are making the prescription process easier, faster, and more convenient for both doctors and their patients,” said Bradley McCloskey, PharmD, CEO. “As we continue to launch more product offerings and expand into more states within the next few months, 2024 is poised to become a year of strong growth as we expand our footprint into 14 additional states.” For more information about MediVera Compounding Pharmacy and its services, please visit mediverarx.com or contact Laurie Malseed, Marketing Specialist, at laurie@mediverarx.com or 937-242-0430. About MediVera Since its inception in 1999, MediVera Compounding Pharmacy™ (formerly University Compounding Pharmacy) has been dedicated to providing personalized medicine. With a focus on quality and innovation, MediVera Compounding Pharmacy™ continues to set industry standards, offering tailored solutions to meet the unique needs of healthcare providers and patients. MediVera Compounding Pharmacy™ is currently licensed in and ships to the following 33 states: AZ, CN, CO, DE, FL, GA, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, NH, NJ, NY, OH, PA, RI, SC, SD, TN, VA, VT, WA, WI, WY. Contact Details MediVera Compounding Pharmacy Laurie Malseed +1 937-242-0430 laurie@mediverarx.com

July 16, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Huma completes Series D with total financing of over $80m as it launches Huma Cloud Platform with GenAI integrations to bring digital first care and research to everyone

Huma

Building and launching a scalable digital health product that meets regulatory demands typically takes a few years to deliver. Today, global healthcare AI company Huma Therapeutics Limited is announcing the completion of its Series D funding round to help cut that time down to days as it launches the Huma Cloud Platform. The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research. The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, Huma has now raised over $300m. The Series D saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others. HSBC Bank plc acted as advisor to Huma during the fundraise. Alongside its Series D, Huma is also announcing the launch of its Huma Cloud Platform – a technology ecosystem designed not only to support the company’s own digital health initiatives, but also to empower others to launch and scale their projects efficiently. With its Huma Cloud Platform and the regulatory foundation that it is built on, Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days. The Huma Cloud Platform is built to serve the company's existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb, India CDSCO Class C and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. The regulatory status of the Huma Cloud Platform significantly reduces the cost, time, and risks associated with bringing digital health projects to life. Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions. Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.” “Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can't scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.” To date, Huma’s technology has powered projects in over 3,000 hospitals and clinics. The platform has been used to engage and screen over 35 million individuals, with 1.8 million active users across its products in over 70 countries. Huma’s U.S. business has grown significantly since launch with new reimbursement codes. The RPM product, built on top of the Huma Cloud Platform for respiratory use cases, now covers 140,000 contracted lives. As a result of all these successes, the company has doubled its revenue year-on-year, and is targeting to become profitable this year. Huma also collaborates with over half of the top 20 pharmaceutical companies globally and has been involved in major national healthcare projects worldwide. Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example a feature called “10x Nurse” that significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop. This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways while keeping humans still in the loop. Looking ahead, combining the Huma Cloud Platform with next-generation AI models will enable Huma to have a bigger impact through its digital-first care and research initiatives, as well as supporting small startups and enterprises in launching the digital solutions they need. It promises to do this much faster and cheaper, shifting the focus to project or venture success rather than getting distracted with scaling technology or managing regulatory burdens. Dan Vahdat, Founder and CEO of Huma, said, “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.” About Huma Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies. Huma's technology powers: ● multi-channel patient engagement at population-wide scale for healthcare systems ● remote patient monitoring (RPM) at scale ● companion apps to support patients through treatment and drug therapies ● digital clinical trials, including decentralised trials, to accelerate medical research Huma's regulated Software as a Medical Device, used in its RPM and companion app platforms, is the only disease- and device- agnostic platform to hold EU MDR Class IIb, US FDA (510-k) Class II clearance and Class IIb registration with the UK MHRA. The SaMD platform is regulated to accept artificial intelligence algorithms and monitor patients of all ages. For more information please visit www.huma.com. Contact Details Huma Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.huma.com/

July 16, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Ultrahuman announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Ultrahuman

Ultrahuman, a pioneer in wearable technology, launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. This is the world’s first in a smart ring form factor. Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals. At the forefront of PowerPlugs is AFib Detection, a PowerPlug that discreetly monitors your heart rhythm every night to detect signs of Atrial Fibrillation (AFib). Ultrahuman Ring AIR is the first smart ring in the world to offer AFib detection. AFib is the most common type of irregular heart rhythm or arrhythmia. It can lead to serious health complications such as stroke and heart failure, if left undetected. Individuals with potential arrhythmia episodes or a history of irregular rhythms can now track AFib closely and seek early intervention. Speaking on the launch, Mohit Kumar, Founder and CEO of Ultrahuman said “When it comes to health, one size doesn’t fit all. That’s why we built PowerPlugs for people to pick and choose what matters most for their health and wellness. Over the next few years, you could expect thousands of applications to be built on top of Ultrahuman’s comprehensive health data platform. Given our most comprehensive data stack of health markers from Ultrahuman Ring, M1 CGM, Ultrahuman Home and more to come, there’s infinite scope to build deep experiences over the next few years. Essentially, your Ultrahuman Ring will keep getting better after your purchase.” “We’re launching our first few PowerPlugs with a novel game changing capability, AFib detection. This life saving technology comes with medical approval in limited markets currently and we’re aggressively launching new markets with regulator’s approval every few weeks.” The PowerPlugs ecosystem can be accessed through the Ultrahuman App and is available in free and premium options. Circadian Rhythm Understanding the importance of aligning with natural circadian rhythms, the Ring AIR provides actionable recommendations tailored to your lifestyle. These suggestions include the optimal times to expose yourself to natural light, exercise, and wind down in the evening, aiming to enhance your energy levels, improve sleep quality, and bolster your overall health. Pregnancy Mode Pregnancy Mode adjusts health monitoring and recommendations specifically for pregnancy. It provides tailored advice on nutrition, activity levels, and health metrics that are crucial during this time. Gain insights into how to maintain your health and your baby's development, with safety and well-being as the priority. Cycle Tracking Cycle Tracking offers a comprehensive overview of your menstrual cycle phases and predicts upcoming cycles with high accuracy. This tool provides personalized insights into your fertility windows and symptom patterns, enabling proactive health management and lifestyle adjustments. Empower yourself with knowledge to make informed decisions about your reproductive health. Caffeine Window Track and optimize your consumption of stimulants such as caffeine throughout the day. By understanding your body's response to different stimulants, this tool advises on the best times for consumption to boost your alertness without affecting your nightly rest. Ideal for maintaining high energy levels and ensuring restful sleep. Vitamin D Manage Vitamin D intake through sun exposure. The app calculates the optimal times for you to step outside, based on your skin type, location, and current UV index, ensuring you get the most effective and safe sun exposure. It focuses on skin absorption, telling you precisely when to go out and estimating how much Vitamin D (in IU) your skin will absorb during your session. With real-time tracking and safety alerts to prevent overexposure, this PowerPlug makes maintaining healthy Vitamin D levels effortless and personalized. Jet Lag Jet Lag PowerPlug features personalized jet lag plans based on the users' travel itineraries, sleep patterns, and chronotypes, leveraging evidence-based methods involving light exposure, melatonin supplements, caffeine, and naps. It offers detailed schedules to follow before, during, and after trips, helping reset the circadian clock efficiently. Weight loss Integrate meal planning with real-time glucose monitoring to optimize your fitness journey. Ultrahuman Ring AIR tracks calories burnt throughout the day. It syncs with automated food logging to provide a comprehensive view of calorie intake versus expenditure. This helps users maintain a balanced diet and work towards their fitness goals without the hassle of manually logging their data. This is a game changer for anyone optimising their weight loss journey. Ovulation Women can now understand ovulation cycles, helping them better understand their bodies and menstrual health. For women looking to conceive, accurate ovulation detection can significantly increase the chances of pregnancy by identifying the most fertile days. Conversely, for those practising natural family planning methods, knowing the ovulation period can help in avoiding pregnancy. Additionally, continuous monitoring can help identify potential reproductive health issues early, allowing for timely interventions. Ultrahuman’s accessibility to health personalization doesn’t stop there. For the first time ever, developers can get access to Raw PPG, Accelerometer and Temperature data streams from the Ring AIR. Ultrahuman invites developers to build bespoke algorithms on top of these data streams from the Ring AIR using UltraSignal, Ultrahuman Ring AIR’s developer platform. UltraSignal will help fuel more customization and innovation in health. Developers can build custom algorithms for Sleep, Stress, Movement, Fertility and more, creating their own Powerplug. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. Ultrahuman’s products include the Ultrahuman M1(continuous glucose monitoring sensor), the Ultrahuman Ring and Blood Vision, a preventive blood testing platform with the pioneering UltraTrace™ technology. By collating different biomarkers, Ultrahuman is helping people improve their energy levels and lifestyle, track their workout, sleep and recovery, and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Ultrahuman Hisham Syed hisham@ultrahuman.com Company Website https://www.ultrahuman.com/

July 16, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Reid Hoffman Wished Death Upon Trump & Funded ‘Lawfare;’ He Must Be Removed from Microsoft’s Board & Defense Innovation Board

NLPC

Following the assassination attempt of former President Donald Trump in Butler, Pa. on Saturday, National Legal and Policy Center (NLPC) is calling upon tech entrepreneur Reid Hoffman to resign his seat on the board of directors for Microsoft Corporation. Should he refuse to step down, then the Microsoft Chairman and Lead Independent Director must take steps along with fellow directors to remove him. The shareholder group is also calling for Hoffman’s removal from the Defense Innovation Board (DIB), a body organized under the Federal Advisory Committee Act to make recommendations regarding technological modernization of the military. DIB is currently chaired by Michael Bloomberg. At the billionaires’ retreat in Sun Valley, Idaho, this week, Mr. Hoffman reportedly engaged in a vigorous debate with fellow tech executive Peter Thiel over how the LinkedIn co-founder’s funding of “lawfare” has turned Trump into a “martyr.” According to a report by Puck News, Mr. Hoffman responded to Mr. Thiel, “Yeah, I wish I had made him an actual martyr.” Previously, Hoffman was also widely known for introducing Jeffrey Epstein to other Silicon Valley figures. According to Luke Perlot, associate director of NLPC’s Corporate Integrity Project: “As shareholders of Microsoft, we call on Mr. Hoffman to resign, or be removed, from the board of directors. His ongoing presence on the board is a stain on Microsoft’s reputation and would implicitly condone his statements and actions.” According to Paul Chesser, director of NLPC’s Corporate Integrity Project: “Sarcasm or not, Hoffman has made clear that he doesn’t think Donald Trump has any civil rights, and that he and other billionaires should pick the president, not the American people. Some holders of great wealth seek to help the less fortunate or promote freedom and decency. Hoffman has instead sought to undermine democratic norms and values. We repeat our call that we made last year that Mr. Hoffman be removed from Microsoft’s board as well as the Defense Innovation Board.” According to Peter Flaherty, NLPC Chairman: “The Defense Innovation Board is engaged in the task of using technology to strengthen our defense in a dangerous world. It conducts serious business. It is no place for an unserious character like Reid Hoffman. For one thing, his associations with Jeffrey Epstein make him a security threat. For another, funding lawsuits by the likes of E. Jean Carroll and wishing martyrdom on Donald Trump should disqualify him from any government board or position.” Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

July 14, 2024 09:45 AM Eastern Daylight Time

12345 ... 270